Heart International最新文献_第7页

An Update on Drug-eluting Technology in Peripheral Arteries to Treat Peripheral Arterial Disease. 外周动脉药物洗脱技术治疗外周动脉疾病的研究进展

IF 0.2

Heart International Pub Date : 2021-12-10 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.73

Leonardo Marques, Silke Hopf-Jensen, Michael Preiss, Stefan Mueller-Huelsbeck

引用次数: 2

An Unusual Cause of Pacemaker Lead Displacement: 'Reverse Ratchet' Syndrome. 起搏器导线移位的一个特殊原因：“反向棘轮”综合征。

IF 0.2

Heart International Pub Date : 2021-11-16 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.103

Haytham Enab, Colin Cunnington, Amir Zaidi

引用次数: 1

The HEP-COVID Trial. HEP-COVID试验。

IF 0.2

Heart International Pub Date : 2021-10-21 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.62

Alex C Spyropoulos

引用次数: 1

Comprehensive Review of Complete Versus Culprit-only Revascularization for Multivessel Disease in ST-segment Elevation Myocardial Infarction. st段抬高型心肌梗死多血管病变的完全血管重建术与单纯罪犯血管重建术的综合评价

IF 0.2

Heart International Pub Date : 2021-08-02 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.54

Robin Jacob, Ayaaz K Sachedina, Sachin Kumar

{"title":"Comprehensive Review of Complete Versus Culprit-only Revascularization for Multivessel Disease in ST-segment Elevation Myocardial Infarction.","authors":"Robin Jacob, Ayaaz K Sachedina, Sachin Kumar","doi":"10.17925/HI.2021.15.1.54","DOIUrl":"https://doi.org/10.17925/HI.2021.15.1.54","url":null,"abstract":"Several organizations have developed guidelines for the management of ST-segment elevation myocardial infarction (STEMI). However, the optimal strategy regarding revascularization in the setting of multivessel disease, specifically with regards to culprit vessel versus complete revascularization, continues to evolve. While previous observational studies promoted culprit vessel-only intervention in patients with STEMI, recent randomized controlled trials suggest potential benefits with multivessel revascularization, either at the time of the index event or in a staged fashion, in patients without cardiogenic shock. This may be due to the known instability of non-culprit lesions in the setting of acute coronary syndrome, and the diffuse coronary processes involved. As additional literature examines culprit vessel versus multivessel revascularization strategies, clinicians continue to be tasked with determining optimal treatment plans for their patients and understanding the factors that promote selected revascularization strategies. This review summarizes and discusses observational studies, randomized control trials and current guidelines in order to evaluate optimal reperfusion strategies for patients presenting with STEMI in the setting of multivessel disease.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"54-59"},"PeriodicalIF":0.2,"publicationDate":"2021-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524594/pdf/heart-int-15-54.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40568361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease. 外周动脉疾病中动脉粥样硬化血栓事件二级预防的药物治疗。

IF 0.2

Heart International Pub Date : 2021-07-21 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.14

Justin T Morrison, Judith Hsia, Marc P Bonaca

{"title":"Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease.","authors":"Justin T Morrison, Judith Hsia, Marc P Bonaca","doi":"10.17925/HI.2021.15.1.14","DOIUrl":"https://doi.org/10.17925/HI.2021.15.1.14","url":null,"abstract":"Patients with peripheral artery disease (PAD) are at risk for severe morbidity and mortality, including ischaemic-related events. Furthermore, there is heterogeneity within the PAD population, where the drivers of risk for cardiovascular and limb-specific ischaemic events differ. Patients with PAD with concomitant coronary artery disease are at increased risk for cardiovascular ischaemic events, whereas patients with PAD with a prior history of lower-extremity revascularization are at increased risk for limb-specific ischaemic events. The current therapeutic challenge is identifying these risk factors to tailor therapy optimally for each patient. Additionally, the majority of our current medical therapeutics in patients with PAD have been shown to reduce atherothrombotic events, such as myocardial infarction, stroke and cardiovascular death, with a paucity of medical therapeutics specifically targeting a reduction in limb-specific ischaemic events. Over the past several years, there have been several contemporary clinical trials evaluating antithrombotic agents and their efficacy in reducing limb-specific ischaemic events. Specifically, rivaroxaban, with the addition of aspirin, has emerged as an efficacious therapeutic. In this article, we provide a review of the current clinical burden of PAD, the rationale behind current PAD medical therapeutics and the contemporary trials that have described the benefit of a novel therapeutic in PAD, rivaroxaban.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"14-19"},"PeriodicalIF":0.2,"publicationDate":"2021-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524742/pdf/heart-int-15-14.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40583010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The ACURATE neo™ and neo2™ Valve Systems. accurate neo™和neo2™阀门系统

IF 0.2

Heart International Pub Date : 2021-07-16 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.37

Michael J Reardon

引用次数: 1

Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk. 高心血管风险患者的双重抗血小板疗法。

IF 1.9

Heart International Pub Date : 2021-07-16 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.26

Clifton Espinoza, Debabrata Mukherjee

{"title":"Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk.","authors":"Clifton Espinoza, Debabrata Mukherjee","doi":"10.17925/HI.2021.15.1.26","DOIUrl":"10.17925/HI.2021.15.1.26","url":null,"abstract":"Coronary artery disease (CAD) is prevalent throughout the world, with a significant impact on global health. There is a vast collection of data in the medical literature relating to the topic of dual antiplatelet therapy (DAPT) in patients considered to be at high cardiovascular (CV) risk. In order to perform a narrative review of literature regarding the use of DAPT in patients with high CV risk, PubMed, Google Scholar and Embase were searched for English-language articles from 1985 to December 2020 by using the medical subject heading terms and keywords 'antiplatelet therapy' and 'high-risk cardiovascular disease', alone or in combination. Both authors critically reviewed the design, population characteristics and results of the selected studies. The topic of DAPT in patients with high CV risk is fluid and constantly evolving. The landmark trials of CURE, TRITON-TIMI 38 and PLATO provided evidence for the optimal use of DAPT in patients after acute coronary syndrome, while the CHARISMA and MATCH trials provided guidance for clinicians for their use in patients with stable coronary artery disease. The American College of Cardiology/American Heart Association focused update, published in 2016, and the European Society of Cardiology guidelines, published in 2017, were developed to provide guidance to clinicians based on the available data at the time to be able to choose the appropriate DAPT strategy that would provide patients with the maximum clinical benefit. The management of DAPT in patients with high CV risk is a challenging task, with new data on the subject constantly being reported. Balancing ischaemic benefit with potential bleeding complications adds to the complexity of managing DAPT in these patients. With all the available data and current clinical guidelines, patients deemed at high CV risk should be considered for DAPT, taking into account individual risk:benefit ratio. In most individuals with high CV risk, the net clinical benefit favours the use of DAPT.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"26-36"},"PeriodicalIF":1.9,"publicationDate":"2021-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584145/pdf/heart-int-15-26.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40583009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Rilonacept in Recurrent Pericarditis. 利洛纳肽在复发性心包炎中的作用。

IF 0.2

Heart International Pub Date : 2021-07-16 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.20

Saberio Lo Presti, Tarec K Elajami, Reza Reyaldeen, Chris Anthony, Allan L Klein

{"title":"The Role of Rilonacept in Recurrent Pericarditis.","authors":"Saberio Lo Presti, Tarec K Elajami, Reza Reyaldeen, Chris Anthony, Allan L Klein","doi":"10.17925/HI.2021.15.1.20","DOIUrl":"https://doi.org/10.17925/HI.2021.15.1.20","url":null,"abstract":"Recurrent pericarditis is associated with significant morbidity and adverse impact on quality of life. Contemporary studies have emphasized the key role of autoinflammatory pathways in its pathophysiology, mainly through the activation of inflammasomes and the production of interleukin (IL)-1α and IL-1β. The IL-1 pathway has emerged as a promising target for the treatment of these patients. A novel IL-1 inhibitor, rilonacept, functions as an IL-1 trap binding to the circulating IL-1α and IL-1β mitigating their inflammatory response. Recently, the RHAPSODY phase III clinical trial evaluated the use of rilonacept in patients with recurrent pericarditis, who were refractory to colchicine, or steroid-dependent. Rilonacept significantly reduced symptoms, inflammatory markers and recurrent episodes, and increased successful withdrawal of steroids. The safety profile of the medication is favourable and well tolerated by patients, with local injection site reaction being the most common side effect described. These results have shifted the paradigm of the understanding of the disease and promise to become part of the armamentarium of medications for the standard of care of these patients, with potential use as monotherapy. The changing landscape of therapeutics and pathophysiology warrants increased recognition and understanding from the international cardiology community about this novel drug and its implication in managing these complex patients.The objective of this review is to describe the bio-action of rilonacept in the treatment of recurrent pericarditis.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"20-25"},"PeriodicalIF":0.2,"publicationDate":"2021-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524724/pdf/heart-int-15-20.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40568364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Update on Etripamil Nasal Spray for the At-home Treatment of Acute Paroxysmal Supraventricular Tachycardia. 埃曲帕米鼻喷雾剂用于家庭治疗急性阵发性室上性心动过速的最新进展。

IF 0.2

Heart International Pub Date : 2021-07-15 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.2

Gavin S Chu, Dhiraj Gupta

引用次数: 2

Sodium-glucose Cotransporter 2 Inhibitors' Rise to the Backbone of Heart Failure Management: A Clinical Review. 钠-葡萄糖共转运蛋白2抑制剂在心力衰竭治疗中的作用:临床综述

IF 0.2

Heart International Pub Date : 2021-07-15 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.42

Namit Rohant, Jamie Lw Kennedy

{"title":"Sodium-glucose Cotransporter 2 Inhibitors' Rise to the Backbone of Heart Failure Management: A Clinical Review.","authors":"Namit Rohant, Jamie Lw Kennedy","doi":"10.17925/HI.2021.15.1.42","DOIUrl":"https://doi.org/10.17925/HI.2021.15.1.42","url":null,"abstract":"Sodium-glucose cotransporter (SGLT) 2 inhibitors, or gliflozins, have quickly risen to prominence within the cardiovascular field due to their substantial benefit in the management of heart failure with reduced ejection fraction (HFrEF). SGLT channels are present throughout the body in various isoforms, but SGLT1 and SGLT2 have been the centre of medical investigation due to known genetic mutations. SGLT2 plays a major role in renal re-absorption of glucose, prompting the development of SGLT2 inhibitors to promote glycosuria and aid in diabetes management. The United States Food and Drug Administration requires evaluation of new antidiabetic medications for cardiovascular safety, prompting several randomized controlled trials of SGLT2 inhibitors over the past 5 years. These initial trials demonstrated superiority in cardiovascular outcomes with SGLT2 inhibitor use and suggested particular benefit in heart failure (HF) outcomes, prompting further study of their mechanisms. Subsequent SGLT2 inhibitor studies have demonstrated reductions in HF hospitalizations and cardiovascular mortality in patients with HFrEF, regardless of the presence of diabetes mellitus. In this review, we discuss the mechanism of action and major clinical trial results that have propelled SGLT2 inhibitors into a key role for patients with HFrEF.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"42-48"},"PeriodicalIF":0.2,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524703/pdf/heart-int-15-42.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40568363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0